Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Emma Vilventhraraja"'
Autor:
Jennifer Edelmann, Arran D. Dokal, Emma Vilventhraraja, Karlheinz Holzmann, David Britton, Tetyana Klymenko, Hartmut Döhner, Mark Cragg, Andrejs Braun, Pedro Cutillas, John G. Gribben
Publikováno v:
iScience, Vol 24, Iss 2, Pp 102089- (2021)
Summary: The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their mechanisms of action, with obinutuzumab evoking greater direct B cell death. To characterize the signaling processes responsible for improved B cell killing by ob
Externí odkaz:
https://doaj.org/article/65cb49ad086b46e487c814941865f435
Autor:
John G. Gribben, Mark S. Cragg, Karlheinz Holzmann, Hartmut Döhner, Emma Vilventhraraja, Pedro R. Cutillas, Arran Dokal, David Britton, Jennifer Edelmann, Tetyana Klymenko, Andrejs Braun
Publikováno v:
iScience
iScience, Vol 24, Iss 2, Pp 102089-(2021)
iScience, Vol 24, Iss 2, Pp 102089-(2021)
Summary The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their mechanisms of action, with obinutuzumab evoking greater direct B cell death. To characterize the signaling processes responsible for improved B cell killing by obi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9283ff8e2a5012c0725a3ff3ecec9d2
https://doi.org/10.1016/j.isci.2021.102089
https://doi.org/10.1016/j.isci.2021.102089
Autor:
Ryan Smith, Pedro R. Cutillas, Emma Vilventhraraja, John G. Gribben, Jennifer Edelmann, Karlheinz Holzmann, Arran Dokal, Mark S. Cragg, Hartmut Döhner, Andrejs Braun, David Britton
Publikováno v:
Blood. 134:1579-1579
The anti-CD20 monoclonal antibody (mAb) rituximab in combination with chemotherapy has improved outcomes for patients with CD20+ B-cell lymphoma. Obinutuzumab was developed as an anti-CD20 mAb with enhanced induction of direct B-cell death and antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53112d88dd858a1ec40c22195b19f3b0
https://doi.org/10.1182/blood-2019-128704
https://doi.org/10.1182/blood-2019-128704
Autor:
Arran Dokal, Emma Vilventhraraja, Karlheinz Holzmann, John G. Gribben, David Britton, Andrejs Braun, Pedro R. Cutillas, Mark C Cragg, Jennifer Edelmann
Publikováno v:
Blood. 132:588-588
NOTCH1 is a cell surface receptor, regulation of which depends on the integrity and subsequent cleavage of its inhibitory domain. Subtle mechanical forces transmitted after ligand-binding [Wang et al., 2013] or removal of Ca2+-ions [Rand et al., 2000
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fd7c4e0cb8b2a27cb96f41d53f3d90c
https://doi.org/10.1182/blood-2018-99-116490
https://doi.org/10.1182/blood-2018-99-116490
Publikováno v:
Blood. 128:1763-1763
Diffuse Large B Cell Lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma (NHL) in adults. Since the addition of the Type I anti-CD20 antibody Rituximab to chemotherapy, the overall survival of NHL patients has improved dramatically compared t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4415992975c7f28e71e3e3a6c04a2ae
https://doi.org/10.1182/blood.v128.22.1763.1763
https://doi.org/10.1182/blood.v128.22.1763.1763
Autor:
Mark S. Cragg, Andrejs Ivanov, Eugen Tausch, Emma Vilventhraraja, Tetyana Klymenko, Stephan Stilgenbauer, Sven Estenfelder, Chen Lu, Jennifer Edelmann, John G. Gribben, Stephen A. Beers
Publikováno v:
Blood. 128:971-971
The NOTCH1 gene locusencodes a cell surface receptor which is recurrently mutated in chronic lymphocytic leukemia (CLL), with a rising incidence in higher risk cases. Upon ligand-binding two cleavage events occur. As a consequence the receptor's intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aec613d71689acdaf7ce36eb9299e7d5
https://doi.org/10.1182/blood.v128.22.971.971
https://doi.org/10.1182/blood.v128.22.971.971